PE20210128A1 - Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos - Google Patents
Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismosInfo
- Publication number
- PE20210128A1 PE20210128A1 PE2020000304A PE2020000304A PE20210128A1 PE 20210128 A1 PE20210128 A1 PE 20210128A1 PE 2020000304 A PE2020000304 A PE 2020000304A PE 2020000304 A PE2020000304 A PE 2020000304A PE 20210128 A1 PE20210128 A1 PE 20210128A1
- Authority
- PE
- Peru
- Prior art keywords
- enpp
- phosphodiesterase
- inhibitors
- ectonucleotide pyrophosphatase
- sulfamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
Abstract
SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (X) DONDE Y1, Y2, Y3, Y4, Y5, X, L, L1, R6, R12, R15, R16, R17 Y n SON COMO SE DEFINEN EN LA DESCRIPCION. SON COMPUESTOS PREFERIDOS: N-(2-(1-(2-AMINO-6,7-DIMETOXIQUINAZOLIN-4-IL)PIPERIDIN-4-IL)ETIL)SULFAMIDA; N-(2-(1-(6,7-DIMETOXI-2-(METILAMINO)QUINAZOLIN-4-IL)PIPERIDIN-4-IL)ETIL)SULFAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA PROTEINA ECTONUCLEOTIDO PIROFOSFATASA/FOSFODIESTERASA 1 (ENPP-1) SIENDO UTILES EN EL TRATAMIENTO DE CANCER.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762553043P | 2017-08-31 | 2017-08-31 | |
US201862688662P | 2018-06-22 | 2018-06-22 | |
PCT/US2018/049195 WO2019046778A1 (en) | 2017-08-31 | 2018-08-31 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE (ENPP-1) AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20210128A1 true PE20210128A1 (es) | 2021-01-19 |
Family
ID=65526102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000304A PE20210128A1 (es) | 2017-08-31 | 2018-08-31 | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos |
Country Status (21)
Country | Link |
---|---|
US (2) | US20200291024A1 (es) |
EP (1) | EP3676254A4 (es) |
JP (1) | JP2020532526A (es) |
KR (1) | KR20200047627A (es) |
CN (1) | CN111315723A (es) |
AU (1) | AU2018325445A1 (es) |
BR (1) | BR112020004209A2 (es) |
CA (1) | CA3074013A1 (es) |
CL (1) | CL2020000501A1 (es) |
CO (1) | CO2020003478A2 (es) |
CR (1) | CR20200140A (es) |
DO (1) | DOP2020000050A (es) |
EC (1) | ECSP20020410A (es) |
IL (1) | IL272910A (es) |
MX (1) | MX2020002183A (es) |
PE (1) | PE20210128A1 (es) |
PH (1) | PH12020500396A1 (es) |
RU (1) | RU2020112090A (es) |
SG (1) | SG11202001664VA (es) |
TW (1) | TW201920104A (es) |
WO (1) | WO2019046778A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018049417A1 (en) | 2016-09-12 | 2018-03-15 | Intra-Cellular Therapies, Inc. | Novel uses |
EP4327882A2 (en) | 2017-09-08 | 2024-02-28 | The Board of Trustees of the Leland Stanford Junior University | Enpp1 inhibitors and their use for the treatment of cancer |
WO2019191504A1 (en) * | 2018-03-30 | 2019-10-03 | Mavupharma, Inc. | Ectonucleotide pyrophosphate-phosphodiesterase (enpp) conjugates and uses thereof |
TW202016076A (zh) | 2018-05-31 | 2020-05-01 | 南韓商C&C新藥研究所 | 雜環衍生物及其用途 |
CN109776413A (zh) * | 2019-01-29 | 2019-05-21 | 天津科技大学 | 一种具有降糖活性的异喹啉衍生物和应用 |
JP2022526295A (ja) | 2019-03-19 | 2022-05-24 | スティングレイ・セラピューティクス・インコーポレイテッド | キノリンおよびキナゾリン化合物およびその使用方法 |
KR20220066277A (ko) * | 2019-08-21 | 2022-05-24 | 더 스크립스 리서치 인스티튜트 | 인터페론 유전자의 자극인자 sting의 모노시클릭 효능제 |
AU2020343329A1 (en) * | 2019-09-03 | 2022-03-24 | Intra-Cellular Therapies, Inc. | Methods of treatment |
BR112022004809A2 (pt) | 2019-09-16 | 2022-06-21 | Aten Porus Lifesciences Pvt Ltd | Compostos 2-amino-s6-tiopurina substituídos como inibidores da proteína enpp1 |
US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
US20230121698A1 (en) * | 2019-12-23 | 2023-04-20 | Sanford Burnham Prebys Medical Discovery Institute | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) modulators and uses thereof |
MX2022009534A (es) * | 2020-02-04 | 2022-11-14 | Stingray Therapeutics Inc | Inhibidores de ectonucleotido pirofosfatasa/fosfofiesterasa 1 (enpp1) y metodos de uso de los mismos. |
WO2021203772A1 (en) * | 2020-04-09 | 2021-10-14 | Betta Pharmaceuticals Co., Ltd | Ectonucleotide pyrophosphatase-phosphodiesterase 1 inhibitors,compositions and uses thereof |
TW202208337A (zh) | 2020-05-04 | 2022-03-01 | 美商佛拉斯托醫療公司 | Enpp1之亞胺基硫烷酮抑制劑 |
US20230159469A1 (en) | 2020-05-08 | 2023-05-25 | Txinno Bioscience Inc. | Novel phthalazine derivative having ectonucloeotide pyrophosphatase/phosphodieste rase inhibitory activity, and use thereof |
KR20210136874A (ko) | 2020-05-08 | 2021-11-17 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 프탈라진 유도체 및 이들의 용도 |
CN112174958B (zh) * | 2020-10-29 | 2021-07-20 | 贵州大学 | 一种吡啶并[2,3-d]嘧啶类化合物及其制备方法和用途 |
AU2021368622A1 (en) * | 2020-10-30 | 2023-06-08 | 1Cbio, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (enpp1) inhibitors and uses thereof |
EP4259148A1 (en) * | 2020-12-09 | 2023-10-18 | Stingray Therapeutics, Inc. | Phosphonates as inhibitors of enpp1 and cdnp |
WO2022146022A1 (ko) | 2020-12-29 | 2022-07-07 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
KR20220095154A (ko) | 2020-12-29 | 2022-07-06 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 나프티리딘온 유도체 및 이들의 용도 |
KR20220110118A (ko) | 2021-01-29 | 2022-08-05 | 주식회사 티씨노바이오사이언스 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 벤조트리아졸 유도체 및 이들의 용도 |
US20240116882A1 (en) * | 2021-01-29 | 2024-04-11 | Txinno Bioscience Inc. | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof |
WO2022197734A1 (en) * | 2021-03-16 | 2022-09-22 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
WO2022212488A1 (en) * | 2021-03-31 | 2022-10-06 | Riboscience Llc | Bicyclic heteroaryl phosphonate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
KR102635126B1 (ko) | 2021-05-27 | 2024-02-13 | 한국과학기술연구원 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도 |
WO2023036289A1 (zh) | 2021-09-10 | 2023-03-16 | 上海海和药物研究开发股份有限公司 | 具有enpp1抑制活性的异羟基肟酸类化合物及其用途 |
WO2023075529A1 (ko) * | 2021-10-29 | 2023-05-04 | 보로노이바이오 주식회사 | 퀴나졸린 유도체 화합물 및 이의 용도 |
WO2023086638A1 (en) * | 2021-11-15 | 2023-05-19 | Vir Biotechnology, Inc. | Enpp1 modulators and uses thereof |
KR20230090463A (ko) | 2021-12-15 | 2023-06-22 | 한국과학기술연구원 | 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피리도피리미딘 유도체 및 이들의 용도 |
US20230346771A1 (en) * | 2022-04-29 | 2023-11-02 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
WO2023225001A1 (en) * | 2022-05-16 | 2023-11-23 | Vir Biotechnology, Inc. | Naphthyridine based enpp1 modulators and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2609919A3 (en) * | 2003-09-26 | 2014-02-26 | Exelixis, Inc. | c-Met modulators and methods of use |
US20070232660A1 (en) * | 2006-04-04 | 2007-10-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
WO2008042867A2 (en) * | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
MX2010011224A (es) * | 2008-04-16 | 2011-02-25 | Max Planck Ges Zur Fa Rderung Der Wissenschaften E V | Derivados de quinoleina como inhibidores de la cinasa axl. |
EP2311809A1 (en) * | 2009-10-16 | 2011-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Quinolinyloxyphenylsulfonamides |
CA2684017A1 (en) * | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
WO2014160177A2 (en) * | 2013-03-13 | 2014-10-02 | Exelixis, Inc. | Quinazoline inhibitors of pi3k |
JP6617155B6 (ja) * | 2015-04-07 | 2020-01-22 | グアンドン・レイノーヴェント・バイオテック・カンパニー・リミテッド | チロシンキナーゼ阻害剤およびそれを含む医薬組成物 |
JP2020504740A (ja) * | 2016-12-22 | 2020-02-13 | マブファーマ,インク. | ホスホジエステラーゼ阻害剤および微生物処置の方法 |
-
2018
- 2018-08-31 CN CN201880070160.XA patent/CN111315723A/zh active Pending
- 2018-08-31 RU RU2020112090A patent/RU2020112090A/ru unknown
- 2018-08-31 CR CR20200140A patent/CR20200140A/es unknown
- 2018-08-31 MX MX2020002183A patent/MX2020002183A/es unknown
- 2018-08-31 EP EP18852452.4A patent/EP3676254A4/en active Pending
- 2018-08-31 TW TW107130589A patent/TW201920104A/zh unknown
- 2018-08-31 JP JP2020512365A patent/JP2020532526A/ja active Pending
- 2018-08-31 AU AU2018325445A patent/AU2018325445A1/en not_active Abandoned
- 2018-08-31 BR BR112020004209-9A patent/BR112020004209A2/pt unknown
- 2018-08-31 WO PCT/US2018/049195 patent/WO2019046778A1/en unknown
- 2018-08-31 PE PE2020000304A patent/PE20210128A1/es unknown
- 2018-08-31 US US16/639,944 patent/US20200291024A1/en not_active Abandoned
- 2018-08-31 SG SG11202001664VA patent/SG11202001664VA/en unknown
- 2018-08-31 KR KR1020207008997A patent/KR20200047627A/ko not_active Application Discontinuation
- 2018-08-31 CA CA3074013A patent/CA3074013A1/en active Pending
-
2020
- 2020-02-26 IL IL272910A patent/IL272910A/en unknown
- 2020-02-27 PH PH12020500396A patent/PH12020500396A1/en unknown
- 2020-02-28 DO DO2020000050A patent/DOP2020000050A/es unknown
- 2020-02-28 CL CL2020000501A patent/CL2020000501A1/es unknown
- 2020-03-25 CO CONC2020/0003478A patent/CO2020003478A2/es unknown
- 2020-03-27 EC ECSENADI202020410A patent/ECSP20020410A/es unknown
-
2022
- 2022-03-23 US US17/702,597 patent/US20230183239A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DOP2020000050A (es) | 2020-08-15 |
CN111315723A (zh) | 2020-06-19 |
US20230183239A1 (en) | 2023-06-15 |
US20200291024A1 (en) | 2020-09-17 |
TW201920104A (zh) | 2019-06-01 |
EP3676254A1 (en) | 2020-07-08 |
ECSP20020410A (es) | 2020-06-30 |
PH12020500396A1 (en) | 2021-01-04 |
BR112020004209A2 (pt) | 2020-09-01 |
AU2018325445A1 (en) | 2020-03-19 |
WO2019046778A1 (en) | 2019-03-07 |
CO2020003478A2 (es) | 2020-04-13 |
JP2020532526A (ja) | 2020-11-12 |
CL2020000501A1 (es) | 2020-07-10 |
RU2020112090A3 (es) | 2022-03-28 |
SG11202001664VA (en) | 2020-03-30 |
RU2020112090A (ru) | 2021-10-04 |
EP3676254A4 (en) | 2021-01-13 |
KR20200047627A (ko) | 2020-05-07 |
CR20200140A (es) | 2020-05-15 |
CA3074013A1 (en) | 2019-03-07 |
MX2020002183A (es) | 2020-10-05 |
IL272910A (en) | 2020-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20210128A1 (es) | Inhibidores de la ectonucleotido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos | |
CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
PE20151274A1 (es) | Inhibidores de erk y sus usos | |
PE20180160A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
PE20170695A1 (es) | Compuestos de indol carboxamida utiles como inhibidores de cinasas | |
PE20210372A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
PE20170666A1 (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
PE20161427A1 (es) | Inhibidores heteroarilo de syk | |
PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
CL2009000323A1 (es) | Compuestos derivados de heterociclos no condensados sustituidos, inhibidores de la funcion de la proteina ns5a; composicion farmaceutica que los comprende; y su uso para tratar la infeccion del virus de la hepatitis c. | |
PE20170705A1 (es) | Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion) | |
CY1124913T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης ως διαμορφωτες υποδοχεα pge2 | |
PE20151413A1 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
PE20141855A1 (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
PE20161073A1 (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
CL2009000394A1 (es) | Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer. | |
EA201200653A1 (ru) | Гетариламинохинолины | |
EA200901157A1 (ru) | Конденсированные кольцевые гетероциклические модуляторы киназы | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20061436A1 (es) | Derivados de amida sustituida como inhibidores de proteina quinasa | |
EA200700142A1 (ru) | Замещенные гетероциклом циклические производные мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы | |
PE20140302A1 (es) | Inhibidores del virus de la hepatitis c | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
PE20090365A1 (es) | Imidazopirazinas como inhibidores de proteina quinasa |